Healthcare [ 13/13 ] | Biotechnology [ 105/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 24 | -0.3 Decreased by -233.33% | -0.31 Increased by +3.23% |
| Nov 13, 23 | -0.43 Decreased by -290.91% | -0.11 Decreased by -290.91% |
| Aug 11, 23 | -0.54 Decreased by -440% | -0.09 Decreased by -500% |
| Jun 23, 23 | -3.9 Decreased by -4.23 K% | -0.84 Decreased by -364.29% |
| Feb 14, 23 | -0.09 Increased by +18.18% | -0.15 Increased by +40% |
| Nov 14, 22 | -0.11 Decreased by -266.67% | - |
| Aug 11, 22 | -0.1 Decreased by -25% | - |
| Jun 21, 22 | -0.09 Increased by +62.5% | -0.13 Increased by +30.77% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0 Decreased by N/A% | -2.39 M Increased by +38.52% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0 Decreased by N/A% | -3.72 M Increased by +24.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by -100% | -4.02 M Increased by +11.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | -32 K Decreased by -346.15% | -29.09 M Decreased by -623.56% | Increased by +90.9 K% Increased by +393.95% |
| Dec 31, 22 | 0 Decreased by N/A% | -3.89 M Decreased by -2.94% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -4.93 M Decreased by -602.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 32 K Decreased by -72.17% | -4.52 M Decreased by -45.09% | Decreased by -14.14 K% Decreased by -421.43% |
| Mar 31, 22 | 13 K Decreased by -88.7% | -4.02 M Increased by +28.8% | Decreased by -30.92 K% Decreased by -529.85% |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.